BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on December 15, 2025 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2022 Inducement Plan, as amended from time to time. The Inducement Grant was granted as an inducement ...

Core Points - Biomea Fusion, Inc. granted non-qualified stock options to a new employee for 48,000 shares, vesting quarterly over four years [1][2] - The stock option award is part of Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023 [2] - Biomea Fusion focuses on developing oral small molecules for diabetes and obesity treatment, aiming to improve patient lives [3]

Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [3] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization [3] Executive Compensation - The Board of Directors granted CEO Jean-Paul Kress an option to purchase 83,296,638 shares of common stock as an inducement for his employment [1] - The stock option has a ten-year term with an exercise price of $0.89 per share, equal to the closing price on June 26, 2025 [2] - The option will vest over a four-year period, with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months [2]

Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases [3] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, aimed at inhibiting the activity of B cells involved in autoimmune diseases without depleting them [3] - Zenas aims to leverage its experienced leadership and disciplined product acquisition strategy to identify and develop candidates that provide superior clinical benefits for patients with autoimmune diseases [3] Stock Option Grant - On June 16, 2025, Zenas granted a non-qualified stock option to purchase 112,000 shares of common stock to a newly hired employee as an inducement for employment [1] - The stock option has a ten-year term with an exercise price of $9.97, equal to the closing price on the grant date [2] - The option will vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting in 36 equal monthly installments, contingent on the employee's continued service [2]